Identification

Name
Lorazepam
Accession Number
DB00186  (APRD00116)
Type
Small Molecule
Groups
Approved
Description

A benzodiazepine used as an anti-anxiety agent with few side effects. It also has hypnotic, anticonvulsant, and considerable sedative properties and has been proposed as a preanesthetic agent.

Structure
Thumb
Synonyms
  • o-Chlorooxazepam
  • o-Chloroxazepam
External IDs
WY-4036
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AtivanTablet1 mg/1OralA S Medication Solutions2013-05-012017-06-20Us
AtivanTablet2 mg/1OralValeant Pharmaceuticals North America2013-05-01Not applicableUs
AtivanTablet2 mgOralPfizer1994-12-31Not applicableCanada
AtivanTablet1 mg/1OralMckesson Rxpak Inc2013-05-01Not applicableUs
AtivanInjection4 mg/mLIntramuscular; IntravenousWest Ward Pharmaceutical1980-07-25Not applicableUs
AtivanTablet0.5 mgSublingualPfizer1995-12-31Not applicableCanada
AtivanTablet1 mg/1OralValeant Pharmaceuticals North America2013-05-01Not applicableUs
AtivanTablet1 mgSublingualPfizer1994-12-31Not applicableCanada
AtivanTablet1 mg/1OralA S Medication Solutions2010-03-162017-06-20Us
AtivanInjection2 mg/mLIntramuscular; IntravenousWest Ward Pharmaceutical1980-07-25Not applicableUs
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-lorazepam SublingualTablet2 mgSublingualApotex Corporation2013-10-16Not applicableCanada
Apo-lorazepam SublingualTablet0.5 mgSublingualApotex Corporation2013-10-16Not applicableCanada
Apo-lorazepam SublingualTablet1 mgSublingualApotex Corporation2013-10-16Not applicableCanada
Apo-lorazepam Tab 0.5mgTablet0.5 mgOralApotex Corporation1985-12-31Not applicableCanada
Apo-lorazepam Tab 1mgTablet1 mgOralApotex Corporation1985-12-31Not applicableCanada
Apo-lorazepam Tab 2mgTablet2 mgOralApotex Corporation1985-12-31Not applicableCanada
LorazepamTablet2 mg/1OralMc Kesson Contract Packaging2012-10-18Not applicableUs
LorazepamTablet2 mg/1OralRebel Distributors1988-04-15Not applicableUs
LorazepamTablet.5 mg/1OralDirectrx2016-02-18Not applicableUs
LorazepamTablet.5 mg/1OralAidarex Pharmaceuticals LLC2007-10-01Not applicableUs
International/Other Brands
Almazine (Psyco Remedies) / Anxiedin (U-Liang) / Idalprem (Novartis) / Lorabenz / Lorsilan (Belupo) / Somagerol / Temesta (Wyeth) / Wypax (Wyeth KK)
Categories
UNII
O26FZP769L
CAS number
846-49-1
Weight
Average: 321.158
Monoisotopic: 320.011932988
Chemical Formula
C15H10Cl2N2O2
InChI Key
DIWRORZWFLOCLC-UHFFFAOYSA-N
InChI
InChI=1S/C15H10Cl2N2O2/c16-8-5-6-12-10(7-8)13(19-15(21)14(20)18-12)9-3-1-2-4-11(9)17/h1-7,15,21H,(H,18,20)
IUPAC Name
7-chloro-5-(2-chlorophenyl)-3-hydroxy-2,3-dihydro-1H-1,4-benzodiazepin-2-one
SMILES
OC1N=C(C2=CC=CC=C2Cl)C2=C(NC1=O)C=CC(Cl)=C2

Pharmacology

Indication

For the management of anxiety disorders, and for treatment of status epilepticus.

Structured Indications
Pharmacodynamics

Lorazepam, a benzodiazepine not transformed to active metabolites, is used to treat anxiety, status epilepticus, and for sedation induction and anterograde amnesia.

Mechanism of action

Lorazepam binds to an allosteric site on GABA-A receptors, which are pentameric ionotropic receptors in the CNS. Binding potentiates the effects of the inhibitory neurotransmitter GABA, which upon binding opens the chloride channel in the receptor, allowing chloride influx and causing hyperpolerization of the neuron.

TargetActionsOrganism
AGABA-A receptor (anion channel)
positive allosteric modulator
Human
UTranslocator protein
other
Human
Absorption

Readily absorbed with an absolute bioavailability of 90% when given orally. When intramuscularly administered, lorazepam is completely and rapidly absorbed. It achieves max serum concentration in 3 hours. The max serum concentration of a 4 mg dose is 48 ng/mL.

Volume of distribution

1.3 L/kg. Unbound lorazepam can cross the blood-brain-barrier via passive diffusion.

Protein binding

91±2% bound to plasma proteins when given parenterally. When given orally, it is 85% bound to plasma proteins.

Metabolism

Lorazepam is hepatically metabolized and is extensively conjugated to the 3-0-phenolic glucuronide. This is an inactive metabolite and is eliminated mainly by the kidneys.

Route of elimination

When a single 2 mg oral dose is give to healthy subjects, 88±4% of the administered dose was recovered in urine and 7±2% was recovered in feces. The percent of administered dose recovered in urine as lorazepam glucuronide was 74±4%. Only 0.3% of the dose was recovered as unchanged lorazepam, and the remainder of the radioactivity represented minor metabolites.

Half life

Parenteral administration = 14±5 hours; Oral administration = 2 hours.

Clearance

Total clearance, parenteral administration = 1.1±0.4 mL/min/kg.

Toxicity

The most important clinical adverse event caused by lorazepam is respiratory depression. LD50, mouse, oral = 1850 mg/kg.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
7-NitroindazoleThe risk or severity of adverse effects can be increased when Lorazepam is combined with 7-Nitroindazole.Experimental
AcepromazineThe risk or severity of adverse effects can be increased when Lorazepam is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Lorazepam is combined with Aceprometazine.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Lorazepam is combined with Adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Lorazepam is combined with Agomelatine.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Lorazepam is combined with Alaproclate.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Lorazepam is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Lorazepam is combined with Alfentanil.Approved, Illicit
AllopregnanoloneThe risk or severity of adverse effects can be increased when Lorazepam is combined with Allopregnanolone.Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Lorazepam is combined with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Lorazepam is combined with Alphaprodine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Alprazolam.Approved, Illicit, Investigational
Ambroxol acefyllinateThe therapeutic efficacy of Lorazepam can be decreased when used in combination with Ambroxol acefyllinate.Experimental, Investigational
AminophyllineThe therapeutic efficacy of Lorazepam can be decreased when used in combination with Aminophylline.Approved
AmisulprideThe risk or severity of adverse effects can be increased when Lorazepam is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Lorazepam is combined with Amitriptyline.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Lorazepam is combined with Amobarbital.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Lorazepam is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Lorazepam is combined with Amperozide.Experimental
AripiprazoleThe risk or severity of adverse effects can be increased when Lorazepam is combined with Aripiprazole.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Lorazepam is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Lorazepam is combined with Asenapine.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Lorazepam is combined with Azaperone.Investigational, Vet Approved
AzelastineLorazepam may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Lorazepam is combined with Baclofen.Approved
BarbitalThe risk or severity of adverse effects can be increased when Lorazepam is combined with Barbital.Illicit
BenperidolThe risk or severity of adverse effects can be increased when Lorazepam is combined with Benperidol.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Lorazepam is combined with Benzocaine.Approved
Benzyl alcoholThe risk or severity of adverse effects can be increased when Lorazepam is combined with Benzyl alcohol.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Lorazepam is combined with Brexpiprazole.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Lorazepam.Approved
BromazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Bromazepam.Approved, Illicit
BromisovalThe risk or severity of adverse effects can be increased when Lorazepam is combined with Bromisoval.Experimental
BromperidolThe risk or severity of adverse effects can be increased when Lorazepam is combined with Bromperidol.Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Lorazepam is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Brotizolam.Approved, Investigational, Withdrawn
BupivacaineThe risk or severity of adverse effects can be increased when Lorazepam is combined with Bupivacaine.Approved, Investigational
BuprenorphineLorazepam may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Lorazepam is combined with Buspirone.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Lorazepam is combined with Butabarbital.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Lorazepam is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Lorazepam is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Lorazepam is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Lorazepam is combined with Butethal.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Lorazepam is combined with Butorphanol.Approved, Illicit, Vet Approved
CanertinibThe risk or severity of adverse effects can be increased when Lorazepam is combined with Canertinib.Investigational
CarbamazepineThe risk or severity of adverse effects can be increased when Lorazepam is combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Lorazepam is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Lorazepam is combined with Carfentanil.Illicit, Investigational, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Lorazepam is combined with Carisoprodol.Approved
CetirizineThe risk or severity of adverse effects can be increased when Lorazepam is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Lorazepam is combined with Chloral hydrate.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Lorazepam is combined with Chlordiazepoxide.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Lorazepam is combined with Chlormezanone.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Lorazepam is combined with Chloroprocaine.Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Lorazepam is combined with Chlorphenamine.Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Lorazepam is combined with Chlorpromazine.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Lorazepam is combined with Chlorprothixene.Approved, Investigational, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Lorazepam is combined with Chlorzoxazone.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Lorazepam is combined with Cinchocaine.Approved, Vet Approved
CitalopramThe risk or severity of adverse effects can be increased when Lorazepam is combined with Citalopram.Approved
ClemastineThe risk or severity of adverse effects can be increased when Lorazepam is combined with Clemastine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Lorazepam is combined with Clidinium.Approved
ClobazamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Clobazam.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when Lorazepam is combined with clomethiazole.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Lorazepam is combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Lorazepam is combined with Clonidine.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Lorazepam is combined with Clopenthixol.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Lorazepam is combined with Clorazepate.Approved, Illicit
ClothiapineThe risk or severity of adverse effects can be increased when Lorazepam is combined with Clothiapine.Experimental
ClozapineThe risk or severity of adverse effects can be increased when Lorazepam is combined with Clozapine.Approved
CocaineThe risk or severity of adverse effects can be increased when Lorazepam is combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Lorazepam is combined with Codeine.Approved, Illicit
CyclizineThe risk or severity of adverse effects can be increased when Lorazepam is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Lorazepam is combined with Cyclobenzaprine.Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Lorazepam is combined with Cyproheptadine.Approved
DantroleneThe risk or severity of adverse effects can be increased when Lorazepam is combined with Dantrolene.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Lorazepam is combined with Dapiprazole.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Lorazepam is combined with Dapoxetine.Investigational
DeramciclaneThe risk or severity of adverse effects can be increased when Lorazepam is combined with Deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Lorazepam is combined with Desflurane.Approved
DesipramineThe risk or severity of adverse effects can be increased when Lorazepam is combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Lorazepam is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Lorazepam is combined with Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Lorazepam is combined with Detomidine.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Lorazepam is combined with Dexbrompheniramine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Lorazepam is combined with Dexmedetomidine.Approved, Vet Approved
DextromoramideThe risk or severity of adverse effects can be increased when Lorazepam is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Lorazepam is combined with Dextropropoxyphene.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Lorazepam is combined with Dezocine.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Diazepam.Approved, Illicit, Vet Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Lorazepam is combined with Diethyl ether.Experimental
DifenoxinThe risk or severity of adverse effects can be increased when Lorazepam is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Lorazepam is combined with Dihydrocodeine.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Lorazepam is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Lorazepam is combined with Dihydromorphine.Experimental, Illicit
DimenhydrinateThe risk or severity of adverse effects can be increased when Lorazepam is combined with Dimenhydrinate.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Lorazepam is combined with Diphenhydramine.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Lorazepam is combined with Diphenoxylate.Approved, Illicit
DixyrazineThe risk or severity of adverse effects can be increased when Lorazepam is combined with Dixyrazine.Experimental
DoramectinThe risk or severity of adverse effects can be increased when Lorazepam is combined with Doramectin.Vet Approved
DoxepinThe risk or severity of adverse effects can be increased when Lorazepam is combined with Doxepin.Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Lorazepam.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Lorazepam is combined with DPDPE.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Lorazepam.Approved, Illicit
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Lorazepam.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Lorazepam is combined with Drotebanol.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Lorazepam is combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Lorazepam is combined with Dyclonine.Approved
DyphyllineThe therapeutic efficacy of Lorazepam can be decreased when used in combination with Dyphylline.Approved
EcgonineThe risk or severity of adverse effects can be increased when Lorazepam is combined with Ecgonine.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Ecopipam.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Lorazepam is combined with Efavirenz.Approved, Investigational
EltanoloneThe risk or severity of adverse effects can be increased when Lorazepam is combined with Eltanolone.Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Lorazepam is combined with Enflurane.Approved, Investigational, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Lorazepam is combined with Entacapone.Approved, Investigational
EscitalopramThe risk or severity of adverse effects can be increased when Lorazepam is combined with Escitalopram.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Estazolam.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Lorazepam is combined with Eszopiclone.Approved
EthanolLorazepam may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Lorazepam is combined with Ethchlorvynol.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Lorazepam is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Lorazepam is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Lorazepam is combined with Ethyl carbamate.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Lorazepam is combined with Ethyl chloride.Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Lorazepam is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Lorazepam is combined with Ethylmorphine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Lorazepam is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Lorazepam is combined with Etifoxine.Investigational, Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Lorazepam is combined with Etomidate.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Lorazepam is combined with Etoperidone.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Lorazepam is combined with Etorphine.Illicit, Vet Approved
EzogabineThe risk or severity of adverse effects can be increased when Lorazepam is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Lorazepam is combined with Felbamate.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Lorazepam is combined with Fencamfamine.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Lorazepam is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Lorazepam is combined with Fexofenadine.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Lorazepam is combined with Flibanserin.Approved
FluanisoneThe risk or severity of adverse effects can be increased when Lorazepam is combined with Fluanisone.Experimental
FludiazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Fludiazepam.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Lorazepam is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Flunitrazepam.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Lorazepam is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Lorazepam is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Lorazepam is combined with Fluphenazine.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Flurazepam.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Lorazepam is combined with Fluspirilene.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Lorazepam is combined with Fluticasone propionate.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Lorazepam is combined with Fluvoxamine.Approved, Investigational
FosphenytoinThe serum concentration of Fosphenytoin can be increased when it is combined with Lorazepam.Approved
FospropofolThe risk or severity of adverse effects can be increased when Lorazepam is combined with Fospropofol.Approved, Illicit, Investigational
GabapentinThe risk or severity of adverse effects can be increased when Lorazepam is combined with Gabapentin.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Lorazepam is combined with Gabapentin Enacarbil.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Lorazepam is combined with Gamma Hydroxybutyric Acid.Approved, Illicit, Investigational
GepironeThe risk or severity of adverse effects can be increased when Lorazepam is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Lorazepam is combined with Glutethimide.Approved, Illicit
GuanfacineThe risk or severity of adverse effects can be increased when Lorazepam is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Halazepam.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Lorazepam is combined with Haloperidol.Approved
HalothaneThe risk or severity of adverse effects can be increased when Lorazepam is combined with Halothane.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Lorazepam is combined with Heroin.Approved, Illicit, Investigational
HexobarbitalThe risk or severity of adverse effects can be increased when Lorazepam is combined with Hexobarbital.Approved
HyaluronidaseThe therapeutic efficacy of Lorazepam can be decreased when used in combination with Hyaluronidase.Approved, Investigational
HydrocodoneLorazepam may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Lorazepam is combined with Hydromorphone.Approved, Illicit
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Lorazepam.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Lorazepam is combined with Iloperidone.Approved
ImipramineThe risk or severity of adverse effects can be increased when Lorazepam is combined with Imipramine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Lorazepam is combined with Indalpine.Investigational, Withdrawn
IndiplonThe risk or severity of adverse effects can be increased when Lorazepam is combined with Indiplon.Investigational
IsofluraneThe risk or severity of adverse effects can be increased when Lorazepam is combined with Isoflurane.Approved, Vet Approved
KetamineThe risk or severity of adverse effects can be increased when Lorazepam is combined with Ketamine.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Lorazepam is combined with Ketobemidone.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Lorazepam is combined with Lamotrigine.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Levetiracetam.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Lorazepam is combined with Levobupivacaine.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Lorazepam is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Lorazepam is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Lorazepam is combined with Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Lorazepam is combined with Levomethadyl Acetate.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Lorazepam is combined with Levomilnacipran.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Lorazepam is combined with Levorphanol.Approved
LidocaineThe risk or severity of adverse effects can be increased when Lorazepam is combined with Lidocaine.Approved, Vet Approved
LithiumThe risk or severity of adverse effects can be increased when Lorazepam is combined with Lithium.Approved
LofentanilThe risk or severity of adverse effects can be increased when Lorazepam is combined with Lofentanil.Illicit
LoprazolamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Loprazolam.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Lorazepam is combined with Loratadine.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Lormetazepam.Approved
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Lorazepam.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Lorazepam is combined with Lurasidone.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Lorazepam.Approved, Vet Approved
MaprotilineThe risk or severity of adverse effects can be increased when Lorazepam is combined with Maprotiline.Approved
MebicarThe risk or severity of adverse effects can be increased when Lorazepam is combined with Mebicar.Experimental
MeclizineThe risk or severity of adverse effects can be increased when Lorazepam is combined with Meclizine.Approved
MedazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Medazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Lorazepam is combined with Medetomidine.Vet Approved
MefloquineThe therapeutic efficacy of Lorazepam can be decreased when used in combination with Mefloquine.Approved
MelatoninThe risk or severity of adverse effects can be increased when Lorazepam is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Lorazepam is combined with Melperone.Approved, Investigational
MepivacaineThe risk or severity of adverse effects can be increased when Lorazepam is combined with Mepivacaine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Lorazepam is combined with Meprobamate.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Lorazepam is combined with Meptazinol.Experimental
MesoridazineThe risk or severity of adverse effects can be increased when Lorazepam is combined with Mesoridazine.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Lorazepam is combined with Metaxalone.Approved
MethadoneLorazepam may increase the central nervous system depressant (CNS depressant) activities of Methadone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Lorazepam is combined with Methadyl Acetate.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Lorazepam is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Lorazepam is combined with Methaqualone.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Lorazepam is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Lorazepam is combined with Methohexital.Approved
MethotrimeprazineLorazepam may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Lorazepam is combined with Methoxyflurane.Approved, Investigational, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Lorazepam is combined with Methsuximide.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Lorazepam is combined with Methylecgonine.Experimental
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Lorazepam is combined with Methylphenobarbital.Approved
MetyrosineLorazepam may increase the sedative activities of Metyrosine.Approved
MianserinThe therapeutic efficacy of Lorazepam can be decreased when used in combination with Mianserin.Approved, Investigational
MidazolamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Midazolam.Approved, Illicit
MilnacipranThe risk or severity of adverse effects can be increased when Lorazepam is combined with Milnacipran.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Lorazepam.Approved, Investigational
MirtazapineLorazepam may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MolindoneThe risk or severity of adverse effects can be increased when Lorazepam is combined with Molindone.Approved
MorphineThe risk or severity of adverse effects can be increased when Lorazepam is combined with Morphine.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Lorazepam.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Lorazepam is combined with Nalbuphine.Approved
NefazodoneThe risk or severity of adverse effects can be increased when Lorazepam is combined with Nefazodone.Approved, Withdrawn
NitrazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Nitrazepam.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Lorazepam is combined with Nitrous oxide.Approved, Vet Approved
NorfluraneThe risk or severity of adverse effects can be increased when Lorazepam is combined with Norflurane.Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Lorazepam is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Lorazepam is combined with Nortriptyline.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Lorazepam.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Lorazepam is combined with Olopatadine.Approved
OndansetronThe risk or severity of adverse effects can be increased when Lorazepam is combined with Ondansetron.Approved
OpiumThe risk or severity of adverse effects can be increased when Lorazepam is combined with Opium.Approved, Illicit
OrlistatThe serum concentration of Lorazepam can be decreased when it is combined with Orlistat.Approved, Investigational
OrphenadrineLorazepam may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Lorazepam is combined with Osanetant.Investigational
OxazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Oxazepam.Approved
OxethazaineThe risk or severity of adverse effects can be increased when Lorazepam is combined with Oxethazaine.Approved, Investigational
OxprenololThe risk or severity of adverse effects can be increased when Lorazepam is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Lorazepam is combined with Oxybuprocaine.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Lorazepam is combined with Oxycodone.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Lorazepam is combined with Oxymorphone.Approved, Investigational, Vet Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Lorazepam is combined with Paliperidone.Approved
ParaldehydeLorazepam may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
ParoxetineThe risk or severity of adverse effects can be increased when Lorazepam is combined with Paroxetine.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Lorazepam is combined with Penfluridol.Experimental
PentazocineThe risk or severity of adverse effects can be increased when Lorazepam is combined with Pentazocine.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Lorazepam is combined with Pentobarbital.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Lorazepam.Approved
PerazineThe risk or severity of adverse effects can be increased when Lorazepam is combined with Perazine.Investigational
PerospironeThe risk or severity of adverse effects can be increased when Lorazepam is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Lorazepam is combined with Perphenazine.Approved
PethidineThe risk or severity of adverse effects can be increased when Lorazepam is combined with Pethidine.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Lorazepam is combined with Phenazocine.Experimental
PhenibutThe risk or severity of adverse effects can be increased when Lorazepam is combined with Phenibut.Experimental
PhenobarbitalThe risk or severity of adverse effects can be increased when Lorazepam is combined with Phenobarbital.Approved
PhenoperidineThe risk or severity of adverse effects can be increased when Lorazepam is combined with Phenoperidine.Experimental
PhenoxyethanolThe risk or severity of adverse effects can be increased when Lorazepam is combined with Phenoxyethanol.Approved
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Lorazepam.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Lorazepam is combined with Pimozide.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Lorazepam is combined with Pipamperone.Approved, Investigational
PipotiazineThe risk or severity of adverse effects can be increased when Lorazepam is combined with Pipotiazine.Approved, Investigational
PiritramideThe risk or severity of adverse effects can be increased when Lorazepam is combined with Piritramide.Investigational
PizotifenThe risk or severity of adverse effects can be increased when Lorazepam is combined with Pizotifen.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Lorazepam is combined with Pomalidomide.Approved
PramipexoleLorazepam may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Lorazepam is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Prazepam.Approved, Illicit
PregabalinThe risk or severity of adverse effects can be increased when Lorazepam is combined with Pregabalin.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Lorazepam is combined with Prilocaine.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Lorazepam is combined with Primidone.Approved, Vet Approved
ProbenecidThe serum concentration of Lorazepam can be increased when it is combined with Probenecid.Approved
ProcaineThe risk or severity of adverse effects can be increased when Lorazepam is combined with Procaine.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Lorazepam is combined with Prochlorperazine.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Lorazepam is combined with Promazine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Lorazepam is combined with Promethazine.Approved
PropanididThe risk or severity of adverse effects can be increased when Lorazepam is combined with Propanidid.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Lorazepam is combined with Proparacaine.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Lorazepam is combined with Propofol.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Lorazepam is combined with Propoxycaine.Approved
ProtriptylineThe risk or severity of adverse effects can be increased when Lorazepam is combined with Protriptyline.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Lorazepam is combined with Proxibarbal.Experimental
PSD502The risk or severity of adverse effects can be increased when Lorazepam is combined with PSD502.Investigational
QuazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Quazepam.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Lorazepam is combined with Quetiapine.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Lorazepam is combined with Quinisocaine.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Lorazepam is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Lorazepam is combined with Ramelteon.Approved, Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Lorazepam is combined with Remifentanil.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Lorazepam is combined with Remoxipride.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Lorazepam is combined with Reserpine.Approved, Investigational
RisperidoneThe risk or severity of adverse effects can be increased when Lorazepam is combined with Risperidone.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Lorazepam is combined with Ritanserin.Investigational
RomifidineThe risk or severity of adverse effects can be increased when Lorazepam is combined with Romifidine.Vet Approved
RopiniroleLorazepam may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Lorazepam is combined with Ropivacaine.Approved
RotigotineLorazepam may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Lorazepam.Approved
ScopolamineThe risk or severity of adverse effects can be increased when Lorazepam is combined with Scopolamine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Lorazepam is combined with Secobarbital.Approved, Vet Approved
SepranoloneThe risk or severity of adverse effects can be increased when Lorazepam is combined with Sepranolone.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Lorazepam is combined with Sertindole.Approved, Investigational, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Lorazepam is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Lorazepam is combined with Sevoflurane.Approved, Vet Approved
StiripentolThe risk or severity of adverse effects can be increased when Lorazepam is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Lorazepam is combined with Sufentanil.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Lorazepam is combined with Sulpiride.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Lorazepam is combined with Sultopride.Experimental
SuvorexantLorazepam may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TandospironeThe risk or severity of adverse effects can be increased when Lorazepam is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Lorazepam.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Lorazepam is combined with Tasimelteon.Approved
TeduglutideThe serum concentration of Lorazepam can be increased when it is combined with Teduglutide.Approved
TemazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Temazepam.Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Lorazepam is combined with Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Lorazepam is combined with Tetracaine.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Lorazepam is combined with Tetrahydropalmatine.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Lorazepam is combined with Tetrodotoxin.Investigational
ThalidomideLorazepam may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheophyllineThe therapeutic efficacy of Lorazepam can be decreased when used in combination with Theophylline.Approved
ThiamylalThe risk or severity of adverse effects can be increased when Lorazepam is combined with Thiamylal.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Lorazepam is combined with Thiopental.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Lorazepam is combined with Thioridazine.Approved, Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Lorazepam is combined with Thiothixene.Approved
TiagabineThe risk or severity of adverse effects can be increased when Lorazepam is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Lorazepam is combined with Tiapride.Approved, Investigational
TiletamineThe risk or severity of adverse effects can be increased when Lorazepam is combined with Tiletamine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Lorazepam is combined with Tilidine.Experimental
TizanidineThe risk or severity of adverse effects can be increased when Lorazepam is combined with Tizanidine.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Lorazepam is combined with Tolcapone.Approved, Withdrawn
TopiramateThe risk or severity of adverse effects can be increased when Lorazepam is combined with Topiramate.Approved
TramadolThe risk or severity of adverse effects can be increased when Lorazepam is combined with Tramadol.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Lorazepam is combined with Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Lorazepam is combined with Tranylcypromine.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Lorazepam is combined with Trazodone.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Triazolam.Approved
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Lorazepam is combined with Tricaine methanesulfonate.Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Lorazepam is combined with Trichloroethylene.Experimental
TrifluoperazineThe risk or severity of adverse effects can be increased when Lorazepam is combined with Trifluoperazine.Approved
TrifluperidolThe risk or severity of adverse effects can be increased when Lorazepam is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Lorazepam is combined with Triflupromazine.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Lorazepam is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Lorazepam is combined with Triprolidine.Approved
Valproic AcidThe serum concentration of Lorazepam can be increased when it is combined with Valproic Acid.Approved, Investigational
VenlafaxineThe risk or severity of adverse effects can be increased when Lorazepam is combined with Venlafaxine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Lorazepam is combined with Veralipride.Experimental
VigabatrinThe risk or severity of adverse effects can be increased when Lorazepam is combined with Vigabatrin.Approved
Vinyl etherThe risk or severity of adverse effects can be increased when Lorazepam is combined with Vinyl ether.Experimental
VortioxetineThe risk or severity of adverse effects can be increased when Lorazepam is combined with Vortioxetine.Approved
XenonThe risk or severity of adverse effects can be increased when Lorazepam is combined with Xenon.Experimental
XylazineThe risk or severity of adverse effects can be increased when Lorazepam is combined with Xylazine.Vet Approved
YohimbineThe therapeutic efficacy of Lorazepam can be decreased when used in combination with Yohimbine.Approved, Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Lorazepam is combined with Zaleplon.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Lorazepam is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Lorazepam is combined with Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Lorazepam is combined with Ziprasidone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Zolazepam.Vet Approved
ZolpidemLorazepam may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Lorazepam is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Lorazepam is combined with Zopiclone.Approved
ZotepineThe risk or severity of adverse effects can be increased when Lorazepam is combined with Zotepine.Approved, Investigational
ZuclopenthixolThe risk or severity of adverse effects can be increased when Lorazepam is combined with Zuclopenthixol.Approved, Investigational
Food Interactions
  • Avoid alcohol.
  • Avoid excessive quantities of coffee or tea (Caffeine).
  • Take with food.

References

Synthesis Reference

Igor Lifshitz, "Process for preparing pure crystalline lorazepam." U.S. Patent US20010039340, issued November 08, 2001.

US20010039340
General References
  1. Kemper N, Poser W, Poser S: [Benzodiazepine dependence: addiction potential of the benzodiazepines is greater than previously assumed (author's transl)]. Dtsch Med Wochenschr. 1980 Dec 5;105(49):1707-12. [PubMed:7439058]
  2. Lader M: Short-term versus long-term benzodiazepine therapy. Curr Med Res Opin. 1984;8 Suppl 4:120-6. [PubMed:6144459]
  3. Maltais F, Laberge F, Laviolette M: A randomized, double-blind, placebo-controlled study of lorazepam as premedication for bronchoscopy. Chest. 1996 May;109(5):1195-8. [PubMed:8625666]
  4. Heisterkamp DV, Cohen PJ: The effect of intravenous premedication with lorazepam (ativan), pentobarbitone or diazepam on recall. Br J Anaesth. 1975 Jan;47(1):79-81. [PubMed:238548]
  5. Milligan DW, Howard MR, Judd A: Premedication with lorazepam before bone marrow biopsy. J Clin Pathol. 1987 Jun;40(6):696-8. [PubMed:3611398]
External Links
Human Metabolome Database
HMDB14332
KEGG Drug
D00365
PubChem Compound
3958
PubChem Substance
46508468
ChemSpider
3821
BindingDB
50292627
ChEBI
6539
ChEMBL
CHEMBL580
Therapeutic Targets Database
DAP000237
PharmGKB
PA450267
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Lorazepam
ATC Codes
N05BA06 — LorazepamN05BA56 — Lorazepam, combinations
AHFS Codes
  • 28:24.08 — Benzodiazepines
FDA label
Download (540 KB)
MSDS
Download (81.8 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1Active Not RecruitingNot AvailableAAT Deficiency / AATD / Alpha-1 Antitrypsin Deficiency / Fibrosis, Liver1
1CompletedNot AvailableHealthy Volunteers2
1CompletedNot AvailableRecreational CNS Depressant Use1
1CompletedBasic ScienceAlzheimer's Disease (AD)1
1CompletedBasic ScienceEpilepsies1
1CompletedBasic ScienceHealthy Volunteers3
1CompletedDiagnosticHealthy Volunteers1
1CompletedSupportive CareCatatonia / Nodding Syndrome1
1CompletedTreatmentDementias1
1CompletedTreatmentMajor Depressive Disorder (MDD)1
1CompletedTreatmentVoice Disorders1
1CompletedTreatmentRefractory seizure disorders1
1Not Yet RecruitingPreventionPost-Operative Delirium1
1TerminatedDiagnosticSchizophrenic Disorders1
1, 2WithdrawnTreatmentSodium Oxybate / Substance-Related Disorders1
2Active Not RecruitingPreventionDelirium1
2Active Not RecruitingSupportive CareAdvanced Cancers1
2CompletedBasic ScienceReflex Epilepsy, Photosensitive1
2CompletedTreatmentAlcohol Withdrawal Syndrome(AWS)1
2CompletedTreatmentAlcoholism1
2CompletedTreatmentAnxiety Disorders1
2CompletedTreatmentBipolar Disorder (BD) / Mania / Manic Disorder / Manic syndromes / Schizoaffective Disorders1
2CompletedTreatmentCocaine Dependence Related Impairments in Motivation for Change, and in Cue-induced Arousal / Dependence, Cocaine1
2Not Yet RecruitingTreatmentObsessive-Compulsive Disorder (OCD)1
2RecruitingTreatmentEpilepsies1
2RecruitingTreatmentFeeling Anxious1
2TerminatedSupportive CareNausea / Unspecified Childhood Solid Tumor, Protocol Specific / Vomiting1
2, 3CompletedTreatmentCritical Illness1
2, 3CompletedTreatmentRefractory seizure disorders1
2, 3WithdrawnTreatmentSeizures1
3CompletedBasic ScienceHealthy Volunteers1
3CompletedTreatmentAcute Agitation / Schizoaffective Disorders / Schizophrenic Disorders1
3CompletedTreatmentConvulsions / Refractory seizure disorders1
3CompletedTreatmentPerioperative Anxiety1
3CompletedTreatmentRefractory seizure disorders / Seizures1
3CompletedTreatmentSleep Initiation and Maintenance Disorders1
3CompletedTreatmentVertigo, Peripheral1
3CompletedTreatmentRefractory seizure disorders3
3RecruitingTreatmentEpilepsies / Refractory seizure disorders1
3TerminatedTreatmentAnxiety Disorders / Dementias / Depressive State / Psychosomatic Disorders / Schizophrenic Disorders1
3TerminatedTreatmentConvulsions / Refractory seizure disorders1
3TerminatedTreatmentSleep Initiation and Maintenance Disorders1
3Unknown StatusBasic ScienceVolunteers Aged Between 65 and 75 Years Old1
3Unknown StatusTreatmentEpilepsia Partialis Continua / Epilepsies / Kojewnikov's Epilepsy1
4CompletedNot AvailableCognitive Deficits1
4CompletedDiagnosticAnxiety Disorders / Generalized Anxiety Disorder (GAD)1
4CompletedTreatmentAcute Agitation1
4CompletedTreatmentAcute Alcohol Withdrawal Syndrome / Alcohol Withdrawal Syndrome(AWS)1
4CompletedTreatmentAlcoholism1
4CompletedTreatmentFeeling Anxious1
4CompletedTreatmentGeneralized Anxiety Disorder (GAD)1
4CompletedTreatmentSedation therapy1
4RecruitingPreventionAlcohol Dependence / Alcohol Use Disorder (AUD) / Alcohol Withdrawal Syndrome(AWS) / Heavy Drinking / Traumas1
4RecruitingTreatmentAlcohol Withdrawal Syndrome(AWS)1
4RecruitingTreatmentAnticholinergics Toxicity1
4RecruitingTreatmentCardiac Arrest / Hypothermia1
4RecruitingTreatmentHaloperidol Causing Adverse Effects in Therapeutic Use / Lorazepam Causing Adverse Effects in Therapeutic Use / Loxapine Causing Adverse Effects in Therapeutic Use / Psychomotor Agitation1
4RecruitingTreatmentOral Sedation and Cervical Dilator Pain1
4RecruitingTreatmentSedation in Intensive Care Unit Patients1
4Unknown StatusSupportive CarePatient Satisfaction for Bronchoscopy1
Not AvailableCompletedNot AvailableHealthy Volunteers1
Not AvailableCompletedBasic ScienceAnxiety Disorders1
Not AvailableCompletedBasic ScienceCognition1
Not AvailableCompletedBasic ScienceHealthy Volunteers2
Not AvailableCompletedPreventionAlcohol Withdrawal Delirium1
Not AvailableCompletedScreeningAlzheimer's Disease (AD)1
Not AvailableCompletedSupportive CareFocus of Study: Absorption of the Three Components in the Topical ABH Gel in Healthy Volunteers, and Determine if There Are Any Adverse Effects / Healthy Volunteers1
Not AvailableCompletedSupportive CareNausea / Vomiting1
Not AvailableCompletedTreatmentAlcohol Withdrawal Syndrome(AWS)1
Not AvailableCompletedTreatmentBenign Paroxysmal Positional Vertigo (BPPV)1
Not AvailableCompletedTreatmentContraception / Inhalation of Nitrous Oxide1
Not AvailableCompletedTreatmentDepressive Disorders / Depressive State / Major Depressive Disorder (MDD) / Unipolar Depression1
Not AvailableCompletedTreatmentOpiate Addiction1
Not AvailableEnrolling by InvitationSupportive CareInfertilities / Subfertility1
Not AvailableRecruitingBasic SciencePain1
Not AvailableRecruitingTreatmentAnoxic Encephalopathy / Cardiac Arrest / Refractory seizure disorders1
Not AvailableUnknown StatusDiagnosticHealthy Volunteers1
Not AvailableUnknown StatusPreventionPost Traumatic Stress Disorder (PTSD) / Sleep Deprivation1
Not AvailableUnknown StatusSupportive CareNon-Hodgkin's Lymphoma (NHL)1
Not AvailableWithdrawnPreventionPolymorphism, Genetic / Prophylaxis against postoperative nausea and vomiting1

Pharmacoeconomics

Manufacturers
  • Amneal pharmaceuticals
  • Paddock laboratories inc
  • Pharmaceutical assoc inc
  • Roxane laboratories inc
  • Baxter healthcare corp anesthesia critical care
  • Akorn inc
  • Baxter healthcare corp anesthesia and critical care
  • Bedford laboratories div ben venue laboratories inc
  • Dava pharmaceuticals inc
  • Hospira inc
  • International medication systems ltd
  • Marsam pharmaceuticals llc
  • Taylor pharmaceuticals
  • Watson laboratories inc
  • Bedford laboratories
  • Biovail laboratories inc
  • Quantum pharmics ltd
  • Actavis elizabeth llc
  • American therapeutics inc
  • Excellium pharmaceutical inc
  • Halsey drug co inc
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Mutual pharmaceutical co inc
  • Mylan pharmaceuticals inc
  • Par pharmaceutical inc
  • Ranbaxy laboratories ltd
  • Sandoz inc
  • Superpharm corp
  • Usl pharma inc
  • Vintage pharmaceuticals inc
  • Warner chilcott div warner lambert co
Packagers
Dosage forms
FormRouteStrength
InjectionIntramuscular; Intravenous4 mg/mL
TabletOral0.5 mg
TabletOral1 mg
TabletOral2 mg
TabletSublingual0.5 mg
TabletSublingual1 mg
TabletSublingual2 mg
LiquidIntramuscular; Intravenous4 mg
SolutionIntramuscular; Intravenous4 mg
ConcentrateOral2 mg/mL
InjectionIntramuscular2 mg/mL
InjectionIntramuscular; Intravenous2 mg/mL
Injection, solutionIntramuscular; Intravenous2 mg/mL
Injection, solutionIntramuscular; Intravenous4 mg/mL
LiquidOral2 mg/mL
Solution, concentrateOral2 mg/mL
TabletOral.5 mg/1
TabletOral1 mg/1
TabletOral1.0 mg
TabletOral2 mg/1
TabletOral2.0 mg
SolutionIntramuscular; Intravenous2 mg
TabletOral.5 mg
Prices
Unit descriptionCostUnit
LORazepam Intensol 2 mg/ml Concentrate 30ml Bottle44.99USD bottle
Lorazepam powder20.81USD g
Lorazepam 4 mg/ml vial9.59USD ml
Lorazepam 2 mg/ml vial2.5USD ml
Ativan 2 mg tablet2.3USD tablet
Ativan 4 mg/ml vial2.16USD ml
Ativan 1 mg tablet1.96USD tablet
Lorazepam intensol 2 mg/ml1.6USD ml
Lorazepam-ns 60 mg/60 ml bag1.53USD ml
Ativan 0.5 mg tablet1.37USD tablet
Lorazepam-d5w 100 mg/100 ml1.16USD ml
Lorazepam-ns 100 mg/100 ml bag1.16USD ml
Lorazepam 2 mg tablet1.01USD tablet
Ativan 2 mg/ml vial0.9USD ml
Lorazepam 1 mg tablet0.69USD tablet
Lorazepam 0.5 mg tablet0.55USD tablet
Ativan 2 mg Sublingual Tablet0.24USD tablet
Ativan 1 mg Sublingual Tablet0.15USD tablet
Ativan 0.5 mg Sublingual Tablet0.12USD tablet
Apo-Lorazepam 2 mg Tablet0.07USD tablet
Novo-Lorazem 2 mg Tablet0.07USD tablet
Pms-Lorazepam 2 mg Tablet0.07USD tablet
Apo-Lorazepam 1 mg Tablet0.05USD tablet
Novo-Lorazem 1 mg Tablet0.05USD tablet
Pms-Lorazepam 1 mg Tablet0.05USD tablet
Apo-Lorazepam 0.5 mg Tablet0.04USD tablet
Novo-Lorazem 0.5 mg Tablet0.04USD tablet
Pms-Lorazepam 0.5 mg Tablet0.04USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)192-194British Patent 1,022,642.
water solubility80 mg/LMERCK INDEX (1996)
logP2.39HANSCH,C ET AL. (1995)
logS-3.6ADME Research, USCD
pKa13MERCK INDEX (1996); pK1
Predicted Properties
PropertyValueSource
Water Solubility0.0176 mg/mLALOGPS
logP2.98ALOGPS
logP3.53ChemAxon
logS-4.3ALOGPS
pKa (Strongest Acidic)10.61ChemAxon
pKa (Strongest Basic)-2.2ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area61.69 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity82.7 m3·mol-1ChemAxon
Polarizability30.33 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9826
Blood Brain Barrier+0.9641
Caco-2 permeable+0.8867
P-glycoprotein substrateSubstrate0.517
P-glycoprotein inhibitor INon-inhibitor0.8866
P-glycoprotein inhibitor IINon-inhibitor0.9167
Renal organic cation transporterNon-inhibitor0.8812
CYP450 2C9 substrateNon-substrate0.7692
CYP450 2D6 substrateNon-substrate0.8685
CYP450 3A4 substrateSubstrate0.5631
CYP450 1A2 substrateInhibitor0.8262
CYP450 2C9 inhibitorNon-inhibitor0.5063
CYP450 2D6 inhibitorNon-inhibitor0.8445
CYP450 2C19 inhibitorInhibitor0.5065
CYP450 3A4 inhibitorNon-inhibitor0.6563
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6407
Ames testNon AMES toxic0.9133
CarcinogenicityNon-carcinogens0.7711
BiodegradationNot ready biodegradable1.0
Rat acute toxicity1.8229 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.999
hERG inhibition (predictor II)Non-inhibitor0.8734
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
GC-MS Spectrum - EI-BGC-MSsplash10-009i-6791000000-942b7493f1e9fc3d12be
Mass Spectrum (Electron Ionization)MSsplash10-002r-4981000000-a567f7beb26ee18d061c
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-001i-0091000000-04730f82e569df7febdd
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-001i-0390000000-dd63d93f2fa81cbb5928
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0udi-0930000000-3ecf1f2f10049a3cfee2
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0udi-0910000000-95d23a9a121bf45ef8bf
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0udi-0900000000-cdbe26e697f259770c28
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0udi-0900000000-4046d54b4dd9bf7968be
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-001i-0091000000-abaf38ed3aa6e7d51245
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-052b-9000000000-dda683413448d0461123
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-00di-0009000000-53bbea620bd1e8b49eb3
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0fb9-0095000000-793565a97e3afc2ce858
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-004i-0090000000-41097b8a64363c5e2f94
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-004i-0290000000-a0694111a3943eca2b53
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-004i-0690000000-5a4728cb7e2473fc6b3c
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-01rf-0940000000-39d041fbab4fb67a5c41
MS/MS Spectrum - , positiveLC-MS/MSsplash10-00b9-0298000000-986499cda13643ef7d85
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-00b9-0196000000-2e53b39b27c66ec73fd2

Taxonomy

Description
This compound belongs to the class of organic compounds known as 1,4-benzodiazepines. These are organic compounds containing a benzene ring fused to a 1,4-azepine.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Benzodiazepines
Sub Class
1,4-benzodiazepines
Direct Parent
1,4-benzodiazepines
Alternative Parents
Alpha amino acids and derivatives / Chlorobenzenes / Aryl chlorides / Secondary carboxylic acid amides / Lactams / Ketimines / Propargyl-type 1,3-dipolar organic compounds / Azacyclic compounds / Alkanolamines / Organopnictogen compounds
show 4 more
Substituents
1,4-benzodiazepine / Alpha-amino acid or derivatives / Chlorobenzene / Halobenzene / Aryl chloride / Aryl halide / Monocyclic benzene moiety / Benzenoid / Carboxamide group / Ketimine
show 19 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein group
Organism
Human
Pharmacological action
Yes
Actions
Positive allosteric modulator
General Function
Inhibitory extracellular ligand-gated ion channel activity
Specific Function
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine...

Components:
References
  1. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456]
  2. ChEMBL Compound Report Card [Link]
Details
2. Translocator protein
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Other
General Function
Cholesterol binding
Specific Function
Can bind protoporphyrin IX and may play a role in the transport of porphyrins and heme (By similarity). Promotes the transport of cholesterol across mitochondrial membranes and may play a role in l...
Gene Name
TSPO
Uniprot ID
P30536
Uniprot Name
Translocator protein
Molecular Weight
18827.81 Da
References
  1. Venneti S, Lopresti BJ, Wiley CA: The peripheral benzodiazepine receptor (Translocator protein 18kDa) in microglia: from pathology to imaging. Prog Neurobiol. 2006 Dec;80(6):308-22. Epub 2006 Dec 6. [PubMed:17156911]
  2. Park CH, Carboni E, Wood PL, Gee KW: Characterization of peripheral benzodiazepine type sites in a cultured murine BV-2 microglial cell line. Glia. 1996 Jan;16(1):65-70. [PubMed:8787774]
  3. Uusi-Oukari M, Korpi ER: Specific alterations in the cerebellar GABA(A) receptors of an alcohol-sensitive ANT rat line. Alcohol Clin Exp Res. 1991 Mar;15(2):241-8. [PubMed:1647706]
  4. Miller EI, Wylie FM, Oliver JS: Detection of benzodiazepines in hair using ELISA and LC-ESI-MS-MS. J Anal Toxicol. 2006 Sep;30(7):441-8. [PubMed:16959136]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Glucuronosyltransferase activity
Specific Function
UDPGTs are of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isozyme displays activity toward several classes of xeno...
Gene Name
UGT2B15
Uniprot ID
P54855
Uniprot Name
UDP-glucuronosyltransferase 2B15
Molecular Weight
61035.815 Da
References
  1. Chung JY, Cho JY, Yu KS, Kim JR, Jung HR, Lim KS, Jang IJ, Shin SG: Effect of the UGT2B15 genotype on the pharmacokinetics, pharmacodynamics, and drug interactions of intravenous lorazepam in healthy volunteers. Clin Pharmacol Ther. 2005 Jun;77(6):486-94. [PubMed:15961980]

Drug created on June 13, 2005 07:24 / Updated on November 13, 2017 21:49